

Product Datasheet

SAGE-718

Catalog No. **BP-01913** · CAS **1629853-48-0** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.


Target

NMDAR, iGluR

Molecular formula **C₂₇H₄₃F₃O₂**

Molecular weight **456.6243**

STRUCTURE



DESCRIPTION

Dalzanemdor (SAGE-718) is an NMDA receptor-positive modulator of metabolism that can be used to study Huntington's chorea, Alzheimer's disease, and cognitive dysfunction.

BIOLOGICAL ACTIVITY

In vivo

SAGE-718 (Dalzanemdor) (5), a potent and high intrinsic activity NMDAR PAM with an optimized pharmacokinetic profile for oral dosing. Compound 5 has completed phase 1 single ascending dose and multiple ascending dose clinical trials and is currently undergoing phase 2 clinical trials for the treatment of cognitive impairment in Huntington's disease.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Beckley, Jacob T et al. "Pharmacological characterization of SAGE-718, a novel positive allosteric modulator of N-methyl-d-aspartate receptors." British journal of pharmacology vol. 181,7 (2024): 1028-1050.

doi:10.1111/bph.16235

[2]. Hill, Matthew D et al. "SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment." Journal of medicinal chemistry vol. 65,13 (2022): 9063-9075.

doi:10.1021/acs.jmedchem.2c00313

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.